An observational study in Arteriovenous Malformation, Gastrointestinal Bleed and Gastric Varices, sponsored by Medtronic Endovascular. Enrolling by invitation at 3 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Medtronic Endovascular (part of Medtronic) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Arteriovenous Malformations with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Arteriovenous Malformations · United States.
Among the 32 studies in Arteriovenous Malformations with a site in United States, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2026, is one of 10 observational ones, and was the 31st registered.
92 studies on the registry are indexed under Arteriovenous Malformations; 29 are open to participants now.
Browse Arteriovenous Malformations studies →7 of the 32 studies in Arteriovenous Malformations with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+
Atavistik Bio, Inc · Sites in United States, Argentina
Ages 18+ · Healthy volunteers
Cure HHT · Sites in United States
Healthy volunteers
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in United States, Brazil, Canada and 3 more countries
Ages 5+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Arteriovenous Malformations studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 6 · Phase 4 1
First in 1993; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 100 across 41 observational studies indexed under Arteriovenous Malformations.
Median enrollment 20 across the 22 interventional studies, 110 across the 10 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Medtronic Endovascular, one of the names counted as Medtronic. Under that name alone:
Medtronic Endovascular is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Medtronic has 3 studies filed under Arteriovenous Malformations — fewer than ten, so there is no comparison to draw.
2 of the studies in Arteriovenous Malformations with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT05406362Vaderis Therapeutics AGAssess Safety and Efficacy of VAD044 in HHT Patients | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Arteriovenous Malformations with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the Case-Specific Health Care Professional (HCP) Clinical Survey for Concerto Versa™ Detachable Coils, also known as the Concerto Versa HCP Clinical Assessment, is to collect early clinical data from HCPs to assess clinical safety and performance of the Concerto Versa™ Detachable Coils, when used in accordance with approved device labeling per the Instructions for Use (IFU). Data collected will generate clinical evidence to quantitatively assess clinical safety and device performance for the purpose of obtaining European Union Medical Device Regulation (EU MDR) approval.
The Concerto Versa™ Health Care Professional (HCP) Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual use case experience following routine utilization of Concerto Versa™ in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural safety incidents and evaluate device performance. At least 30 use cases will be collected and aggregated from participating HCPs. This data collection is a for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.
The Concerto Versa™ Detachable Coil is indicated for arterial and venous embolization in adult patients requiring embolization in the peripheral vasculature.
Inclusion Criteria:
The Concerto Versa™ Detachable Coil is indicated for arterial and venous embolization in adult patients requiring embolization in the peripheral vasculature.
Device: Concerto Versa™ Detachable Coils
Concerto Versa™ detachable coil is indicated for arterial and venous embolization in the peripheral vasculature
Rate of peri-procedural adverse events
The rate of peri-procedural adverse events related to device and/or procedure.
Time frame: During the Index Procedure
Rate of Technical Success
Technical success is defined as successful delivery and detachment of the coil, and removal of the delivery-pusher.
Time frame: During the Index Procedure
Rate of Peri-procedural success
Peri-procedural success is defined as ability of the device to successfully obstruct or reduce the rate of blood flow to the target lesion as determined by physician judgment.
Time frame: During the Index Procedure
Plan to share: No — No patients will be engaged, and no medical records will be accessed or used. Individual HCP responses for each case will be aggregated into a final report.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.